The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 30, 2021

Filed:

Oct. 25, 2017
Applicants:

Inserm (Institut National DE LA Santé ET DE LA Recherche Médicale), Paris, FR;

Université Paris Diderot—paris 7, Paris, FR;

Université DE Montpellier, Montpellier, FR;

Institut Jean Godinot, Reims, FR;

Institut Régional Du Cancer DE Montpellier, Montpellier, FR;

Inventors:

Armand Bensussan, Paris, FR;

Bruno Robert, Montpellier, FR;

Pierre Martineau, Montpellier, FR;

Myriam Chentouf, Montpellier, FR;

Anne Marie-Cardine, Paris, FR;

Jérôme Giustiniani, Reims, FR;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2803 (2013.01); A61K 47/6801 (2017.08); A61K 47/6819 (2017.08); C07K 2317/21 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01);
Abstract

The present invention relates to monoclonal antibodies that bind to the CD160-TM isoform. The inventors developed new monoclonal antibodies which bind to the CD160-TM isoform but dot not bind to the CD160 GPI-anchored isoform not to the CD160 soluble isoform. In particular, the antibodies of the present invention are suitable for amplifying NK cell activation and therefore cytotoxic functions NK cells.


Find Patent Forward Citations

Loading…